Results 191 to 200 of about 164,122 (292)

The establishment of Health and Demographic Surveillance system (HDSS) in Bauchi State North East Nigeria; baseline findings, challenges and lessons learned. [PDF]

Glob Health Action
Muhammad Bose I, Dabo MM, Abdullahi Kobi M, Musa A, Ibrahim Amaya S, Dahiru A, Yaya J, Dattijo LM, Muir JA, Bashir MF.   +9 more
europepmc   +1 more source

The Indian Health and Demographic Surveillance System Network: Opportunity to Generate Evidence for Public Health Policy. [PDF]

Indian J Community Med, 2023
Yadav AK, Patil R, Juvekar S, IHN Network*.   +3 more
europepmc   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

The impact of COVID-19 on mortality among diabetic and hypertensive individuals in coastal communities in Bangladesh: evidence from chakaria health and demographic surveillance system. [PDF]

Popul Health Metr
Chowdhury S, Nishat NH, Paul A, Hasan MM, Alam SS, Fardousi A, Barr BAT, Kabudula CW, Bashingwa JJH, Hanifi SMA.   +9 more
europepmc   +1 more source

Child marriage in rural Bangladesh and impact on obstetric complications and perinatal death: Findings from a health and demographic surveillance system. [PDF]

PLoS One, 2023
Lee KH, Chowdhury AI, Rahman QS, Cunningham SA, Parveen S, Bari S, El Arifeen S, Gurley ES.   +7 more
europepmc   +1 more source

Analysis of clinical investigation (device) initial submissions received by the Medicines and Healthcare products Regulatory Agency between January 2022 and December 2025

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse clinical investigation‐device initial submissions received by the MHRA between January 2022 and December 2025. Methods Data on submissions were extracted from the clinical investigations unit data bank; software as medical devices were not included. The predefined primary end‐point was submission type.
Andrea Manfrin, Mark Grumbridge, Daniel Hill, Crina Cacou, Graham Warren, James Pound, Jacob George, Alejandro F. Frangi   +7 more
wiley   +1 more source

Predicting abnormal birth weight and identifying associated factors using machine learning in the Hararghe Health and Demographic Surveillance System, Ethiopia. [PDF]

BMC Public Health
Abdeta S, Diop O, Cygu S, Drame A, Momanyi R, Endalamaw Dejene B, Tadele M, Sintayehu Y, Barasa M, Woldie M, Girma T, Tsegaye R, Kiragga A, Adnew B, Howe R, Dheresa M, Abdisa A.   +16 more
europepmc   +1 more source

SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022. [PDF]

Influenza Other Respir Viruses, 2023
Kagucia EW, Ziraba AK, Nyagwange J, Kutima B, Kimani M, Akech D, Ng'oda M, Sigilai A, Mugo D, Karanja H, Gitonga J, Karani A, Toroitich M, Karia B, Otiende M, Njeri A, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Voller S, Ochola-Oyier LI, Bottomley C, Nyaguara A, Munywoki PK, Bigogo G, Maitha E, Uyoga S, Gallagher KE, Etyang AO, Barasa E, Mwangangi J, Bejon P, Adetifa IMO, Warimwe GM, Scott JAG, Agweyu A.   +37 more
europepmc   +1 more source

Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

British Journal of Clinical Pharmacology, EarlyView.
. Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.
Niaz Chalabianloo, Sheikh S. Abdullah, Kamran Sedig, Flory T. Muanda   +3 more
wiley   +1 more source